<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baxevanis, C. N.</style></author><author><style face="normal" font="default" size="100%">Tsavaris, N. B.</style></author><author><style face="normal" font="default" size="100%">Papadhimitriou, S. I.</style></author><author><style face="normal" font="default" size="100%">Zarkadis, I. K.</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N. G.</style></author><author><style face="normal" font="default" size="100%">Bastounis, E. A.</style></author><author><style face="normal" font="default" size="100%">Papamichail, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult Aged Antineoplastic Combined Chemotherapy Protocols Carboplatin Cytokines Cytotoxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunologic Female Fluorouracil Granulocyte-Macrophage Colony-Stimulating Factor Humans Killer Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Lymphokine-Activated Killer Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Mixed Male Middle Aged Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Natural Lymphocyte Culture Test</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1997</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/9301443</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">33</style></volume><pages><style face="normal" font="default" size="100%">1202-8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">{In this report, we studied the immunorestorative properties of subcutaneously administered granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with refractory solid tumours receiving second-line chemotherapy. Such patients exhibit abnormal immune responses in vivo and in vitro and, therefore, it was of interest to examine the effect of GM-CSF-induced immunomodulation on clinical response. We examined patients with primary malignant carcinomas (head and neck</style></abstract><work-type><style face="normal" font="default" size="100%">Journal Article</style></work-type></record></records></xml>